Cdp Equity invests 1 billion euros in Angelini Pharma: acquired a share of 23,5% through a capital increase. The transaction accompanies the largest acquisition in the history of the Italian pharmaceutical group: the completion of the purchase of the American company Catalyst Pharmaceuticals, valued at 4,1 billion dollars, equivalent to approximately 3,5 billion euros.
The entry of CDP Equity, the investment holding company of Cassa Depositi e Prestiti, supports Angelini Pharma's international growth, which aims to become a global player in the areas of brain health and rare diseases.
Angelini Pharma accelerates in the United States with Catalyst Pharmaceuticals
With the completion of the transaction, Catalyst Pharmaceuticals officially joins the Angelini group. The American company, listed on the Nasdaq, is thus integrated into the international platform of the Italian group: its shares are delisted from the US list and shareholders are granted a equivalent of $31,50 in cash for each title.
Specializing in neuroscience and rare diseases, Catalyst brings a portfolio of innovative drugs, specific expertise, and a well-established sales network in the United States. For Angelini Pharma, the acquisition represents an acceleration of its international strategy, with immediate access to products and infrastructure that are difficult to replicate quickly through internal growth.
The financial structure of the operation also includes funds managed by Blackstone, with an investment of approximately €1 billion in preferred shares, subject to customary regulatory approvals.
CDP: "Support for the country system"
For CDP Equity, the investment represents a move to support the development of an Italian group with global ambitions.
According to the CEO of Cdp Equity, Fabio Barchiesi, the operation is "a concrete example" of the role that the company intends to play in favor of the country system, supporting strategic companies on their international growth path.
